As part of the International Liver Congress (ILC) 2021, the EASL Takeaways take a look at key topics from the congress, with leading experts discussing the most impactful science and putting it into perspective. In this session join Professors Pierre-Emmanuel Rautou Didier Samuel and Andrés Cárdenas as they discuss key questions in liver cirrhosis and its complications from ILC 2021.
Professor Samuel first explains the effectiveness of anticoagulants in patients with chronic portal vein hypertension without cirrhosis. The panel then explores whether anticoagulants should be used in patients with portal vein thrombosis and cirrhosis, despite the increased risk of bleeding found in patients with chronic liver disease. In the second half of the session, Professor Samuel leads a discussion on the novel DIALIVE liver dialysis device in patients with ACLF, including how it works, its effectiveness and its limitations.